Skip to main content
Fig. 5 | BMC Genomic Data

Fig. 5

From: Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

Fig. 5

A Recaps of alterations in FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP among breast cancer studies in the cBioportal database. B Oncoprint analysis showed genetic alterations of FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP in breast cancer samples from the TCGA study by Ciriello et al. (2015). C Copy number alterations in FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP in breast cancer samples from the TCGA study by Ciriello et al. (2015). Alterations included 1: deep deletion, 2: shallow deletion, 3: diploid, 4: gain, and 5: amplification. mRNA levels in each group were analyzed using one-way ANOVA with Tukey’s multiple comparisons test. Significances are shown as * for p < 0.05, ** for p < 0.01, and **** for p < 0.001

Back to article page

BMC Genomic Data

ISSN: 2730-6844

Contact us